Of greater significance from the clinical perspective was that decreased glucose blood glucose was observed in GHSR+/+ mice fed with HFD after long-term injection of nesfatin-1, suggesting potential treatment effects of chronic treatment with nesfatin-1 in patients suffering from related metabolic diseases. The gene discussed is GHSR; the disease is Other metabolic disease.